Researchers at the Poznan University of Medical Sciences, in Poland, recently suggested a new potential serum biomarker for interstitial lung disease (ILD) in systemic sclerosis patients. The study was published in the journal Revista Brasileira de Reumatologia and is titled “Serum Clara cell 16-kDa…
Pulmonary arterial hypertension (PAH) is one of the most serious health problems associated with systemic sclerosis (SSc). Researchers have found that specific biomarkers, known as autoantibodies, are associated with an increased risk in the development of PAH in people with SSc. It is not yet known, however, whether or not these…
Cytori Therapeutics, Inc., a late stage cell therapy company developing autologous cell therapies from adipose tissue to treat a variety of medical conditions, recently announced the beginning of its U.S. phase III/pivotal STAR clinical trial in the United States that will assess the efficacy of the experimental ECCS-50 therapy. ECCS-50…
Researchers at UCL-Medical School in the United Kingdom recently reported in the journal PLoS One findings supporting a mechanism that leads to skin fibrosis in systemic sclerosis patients. The study is entitled “Partially Evoked Epithelial-Mesenchymal Transition (EMT) Is Associated with Increased TGFβ Signaling…
According to a news release, it was recently reported at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology in June 2015 that the functional disability and fatigue associated with systemic sclerosis remains stable in patients for a period of at least three years. Systemic sclerosis is…
In a recent study published in the Journal of Parenteral & Enteral Nutrition, a team of researchers found that a short-term tailored MNT intervention can improve symptom burden and potentially the appendicular lean height in patients with systemic sclerosis involving the gastrointestinal tract. Scleroderma, or systemic…
According to a news release, it was recently demonstrated at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology on June 2015 that temporomandibular joint disorder (TMJD) is a common medical condition among patients with systemic sclerosis. TMJD refers to a condition characterized by pain and dysfunction…
In a recent study presented during the European League Against Rheumatism Annual European Congress of Rheumatology, patients with gastrointestinal symptoms associated with systemic sclerosis may benefit from IV immunoglobulin therapy treatment. For the study, Raja J. and colleagues recruited 15 patients with a diagnosis of systemic sclerosis (SSc) from the…
A collaboration between Bristol-Myers Squibb Company and The Medical University of South Carolina (MUSC) will focus on translational research for developing scleroderma and other fibrotic disease treatments. The goal is to combine the two teams’ expertise to advance exciting new research into effective therapeutic options for patients with fibrotic disease.
Researchers at Athens Medical School in Greece recently revealed that the drug buspirone offers clinical benefits to systemic sclerosis patients with esophageal dysfunction. The study was recently published in the United European Gastroenterology Journal and is entitled “Beneficial effect of the 5-HT1A receptor…
Get regular updates to your inbox.